Scaling-up treatment of depression and anxiety: a global return on investment analysis

Dan Chisholm, Kim Sweeny, Peter Sheehan, Bruce Rasmussen, Filip Smit, Pim Cuijpers, Shekhar Saxena

Summary

Background Depression and anxiety disorders are highly prevalent and disabling disorders, which result not only in an enormous amount of human misery and lost health, but also lost economic output. Here we propose a global investment case for a scaled-up response to the public health and economic burden of depression and anxiety disorders.

Methods In this global return on investment analysis, we used the mental health module of the OneHealth tool to calculate treatment costs and health outcomes in 36 countries between 2016 and 2030. We assumed a linear increase in treatment coverage. We factored in a modest improvement of 5% in both the ability to work and productivity at work as a result of treatment, subsequently mapped to the prevailing rates of labour participation and gross domestic product (GDP) per worker in each country.

Findings The net present value of investment needed over the period 2016–30 to substantially scale up effective treatment coverage for depression and anxiety disorders is estimated to be US$147 billion. The expected returns to this investment are also substantial. In terms of health impact, scaled-up treatment leads to 43 million extra years of healthy life over the scale-up period. Placing an economic value on these healthy life-years produces a net present value of $310 billion. As well as these intrinsic benefits associated with improved health, scaled-up treatment of common mental disorders also leads to large economic productivity gains (a net present value of $230 billion for scaled-up depression treatment and $169 billion for anxiety disorders). Across country income groups, resulting benefit to cost ratios amount to 2.3–3.0 to 1 when economic benefits only are considered, and 3.3–5.7 to 1 when the value of health returns is also included.

Interpretation Return on investment analysis of the kind reported here can contribute strongly to a balanced investment case for enhanced action to address the large and growing burden of common mental disorders worldwide.

Funding Grand Challenges Canada.

Copyright © Chisholm et al. Open Access article distributed under the terms of CC BY.
Research in context

Systematic review
We did a systematic review of studies published until Jan 1, 2015, of the effect of treatment of depression and anxiety disorders on economic outcomes (return to work, absenteeism, and presenteeism rates). We searched an existing database on psychological treatments of depression, which has been described in detail by Cuijpers and colleagues, and has been used in a series of earlier published meta-analyses. We identified abstracts by combining terms indicative of psychological treatment and depression (both medical subject headings terms and text words; search terms listed in appendix p 4). For this database, we examined 17 061 abstracts from PubMed (4007 abstracts), PsycINFO (3147 abstracts), Embase (5912 abstracts), and the Cochrane Central Register of Controlled Trials (3995 abstracts). We included all randomised trials comparing a psychological treatment with a control condition (waiting list, care as usual, placebo), another psychological treatment, pharmacotherapy, or combined treatment. We excluded studies in adolescents, children, and inpatients, and maintenance trials. We scrutinised all 440 studies identified in this database for economic outcome data. Although four studies had data for functioning at work, they did not report sufficient detail. Accordingly, we did an additional search on May 21, 2015, to widen our search to include anxiety disorders with greater emphasis on economic outcomes in PubMed, EMBASE, PsycINFO and the Cochrane Library (search terms listed in appendix p 5). We found few useful data and these could not be synthesised meta-analytically. The same conclusion was made in a similar review of the scientific literature.

Interpretation
This analysis sets out a model linking the prevalence of depression and anxiety disorders with expected health and economic benefits of scaled-up treatment, including restored labour participation and productivity. Results from the analysis suggest that monetised benefits of better health and labour force outcomes outweigh the costs of achieving them by 2·3–3·0 to 1 when economic benefits only are considered, and 3·3–5·7 to 1 when the value of health returns is also included. Treatment of common mental disorders leads to improvements in economic production and health outcomes. Clinicians should increase the detection and management of people with depression and anxiety disorders.

Here we did a global return on investment analysis for mental health in people aged 15 years and older focusing on depression and anxiety disorders, which are the most prevalent mental disorders. These disorders lead to large losses in work participation and productivity, and yet lend themselves to effective and accessible treatment as part of an integrated programme of chronic disease management.11

Methods
Analytical framework
Because depression and anxiety disorders represent a public health challenge worldwide, we did a global investment appraisal in low-income, middle-income, and high-income countries. The 36 countries for which we modelled costs and benefits of scaled-up treatment, which span all six of WHO’s major regions, account for 80% of the world’s population and 80% of the global burden of depression and anxiety disorders (appendix p 1). Results for these countries were aggregated and reported by income level (low, lower-middle, upper-middle, high). We set the scale-up period at 2016–30, in line with the timeline of the post-2015 Sustainable Development Goals.

The economic and social benefits of good mental health include both its intrinsic value (improved mental health and wellbeing) and also its instrumental value, in terms of being able to form and maintain relationships, to work or pursue leisure interests, and to make decisions in everyday life. To assess the value of these benefits, first we estimated the population in need in each country, then established the health effects of scaled-up coverage of effective intervention, and finally calculated the economic effect of improved mental health outcomes in terms of enhanced labour participation and productivity. Panel 1 provides more detail on the health and economic benefits captured in, and omitted from, the analysis. The key outputs of the model are year-on-year estimates of the total costs of treatment scale-up and system strengthening (ie, the investment), increased healthy life-years gained as a result of treatment (ie, health return), the value associated with better health (ie, the value of health returns), and enhanced levels of productivity (ie, economic return). The stream of costs incurred and benefits obtained between 2016 and 2030 were discounted at a rate of 3%, to give a net present value. All costs and monetised benefits were expressed in constant US$ for the year 2013.

Population and disease modelling
We used the mental health module of the inter-UN agency OneHealth tool to estimate the number of people with depression and anxiety disorders living in the 36 large countries until 2030. Estimates are based on UN population projections and Global Burden of Disease prevalence estimates for 2010.1,13 The global point prevalence rate for anxiety disorders is 7·3%;15 for depression it is 3·2% for men, and 5·5% for women.14 The OneHealth tool also links the epidemiology of depression and anxiety disorders (prevalence, incidence, remission, excess mortality, and disability weight)16–20 to country-specific life tables, so that cases averted and
healthy life-years gained over time at the population level can be estimated. Healthy life-years reflect time spent by the population in a particular state of health with a known degree of disability. Estimation of healthy life-years for depression took into account its association with excess mortality (due to suicide and other causes of death).15

**Intervention effects, costs, and coverage**

**Intervention effects**

We restricted the analysis of interventions within the OneHealth tool to treatment because the evidence on prevention of depression and anxiety is quite weak and of uncertain generalisability to low-income and middle-income country settings.15 In line with WHO's Mental Health Gap Action Programme (mhGAP) intervention guide, modelled interventions included basic psychosocial treatment for mild cases, and either basic or more intensive psychosocial treatment plus antidepressant drug for moderate to severe cases.16 Moderate to severe cases of depression were split into first-episode and recurrent episode cases. We calculated the health effect of treatment in terms of a proportionate improvement in the rate of remission, equivalent to a shortening of the duration of an episode of illness, and also, up to the point of recovery, an improvement in the average level of functioning as reflected in the disability weight for the disorder.16 The appendix shows the effect size estimates and their derivation (appendix p 2); these take into account partial response, the lag time between onset of the disorder and treatment, and expected levels of non-adherence in treated populations.

**Intervention costs**

We worked out total costs in a given year for a country by multiplying resource use needs by their respective unit costs to give a cost per case, which was then multiplied by the total number of cases expected to receive a particular intervention. Country-specific unit costs of inpatient and outpatient care were taken from a WHO database, adjusted to 2013 price levels.17 Treatment costs relied on previous cost-effectiveness studies and resource need profiles garnered from existing treatment guidelines and costing studies.16,18,19 Key categories of resource use were: medication; 6 months continual antidepressant drug (generically produced fluoxetine) was included for moderate to severe cases; outpatient and primary care: regular visits were needed for all cases, ranging from four per case per year for basic psychosocial treatment, up to 14–18 visits for moderate to severe cases receiving antidepressant drug and intensive psychosocial treatment (half of whom are assumed to receive this on an individual basis, the other half in groups); in line with the mhGAP intervention guide, it is envisaged that this care and follow-up would largely be undertaken in non-specialist health care settings by doctors, nurses and psychosocial care providers trained in the identification, assessment, and management of depression and anxiety disorders; and inpatient care: few cases are expected to be admitted to hospital (2–3% of moderate to severe cases only, for an average length of stay of 14 days).

Additionally, we included an estimate of the expected level of programme costs and shared health system resources needed to deliver interventions as part of an

---

**Panel 1: Health, economic, and social benefits of scaled-up treatment for depression and anxiety disorders**

**Health effects**

To establish the effect of treatment, we used rates of improved recovery or remission and levels of functioning. Improved functioning translates into fewer life-years spent by the population in a state of diminished health, whereas an increased rate of remission leads to a decrease in the prevalence of these disorders over time. Depression is also associated with an excess risk of premature mortality because of suicide and other causes of death. We projected a reduction in excess mortality, amounting to an increase in healthy life expectancy, as a result of averting cases of depression in the population. Although depression and anxiety disorders are often comorbid with each other, and with a range of other health disorders (eg, substance use disorder, other non-communicable diseases and, in certain populations, in people with HIV/AIDS) we were not able to account for these comorbidities in the analysis. Additionally, we were unable to capture the positive effect of treatment on the mental and physical health of close family members, including infants of mothers with perinatal depression, despite robust evidence that depression can adversely affect infant attachment and subsequent child growth and cognitive development.

**Economic effects**

A direct potential benefit of successfully treating common mental disorders is a decrease in overall health-care costs. Although interventions have their own costs, these can be more than offset by a reduction in other services, notably hospital-based inpatient episodes or outpatient visits. Reduced use of informal and indigenous health-care providers, such as faith healers or traditional healers, is a further expected source of cost savings in many countries. Estimation of the predicted extent of these cost offsets is very challenging at the international level because it requires detailed information about both the varying level of comorbidity across diverse populations and the typical use of non-intervention related services. Accordingly, we did not explicitly consider such effects in our analysis. Similarly, we did not have sufficient information across countries to model the reduced need for other welfare-related services potentially available to people with depression and anxiety disorders, including unemployment benefit or income support and social or disability assistance. In the mainly high-income countries where such welfare support is widely available, depression and other common mental disorders account for a significant proportion of overall payments. Instead, the analysis focused on the financial benefits flowing from increased rates of workforce participation and productivity. The analysis only considers the contribution to the economy as a whole through increased economic output; it does not estimate the various income shares of this output.

**Social effects**

Conceptually distinct from improvements in clinical functioning (health effect) and the restored ability to do paid work (economic effect), the successful treatment of depression and anxiety disorders leads to improved opportunities for individuals and households to pursue their leisure interests, participate more in social and community activities, and carry out household production roles. The economic worth of these non-market production and welfare gains is incorporated into our estimate of the intrinsic value of mental health.
integrated model of chronic disease management. These include programme management and administration, training and supervision, drug safety monitoring, health promotion and awareness campaigns, and strengthened logistics and information systems. We expressed estimates as an on-cost to the estimated direct healthcare costs. The baseline value for this on-cost was 10% (and therefore grows in absolute terms during scale-up).

Intervention coverage
The appendix provides coverage rates used for each individual intervention at different levels of national income (appendix p 3). Summing across all interventions and their respective populations in need, it is estimated that—depending on the income level of the country—between 7% and 28% of all people with depression currently receive treatment, equivalent to a treatment gap of 72–93% (table 1). A gradual, linear increase in treatment coverage to a third of all cases in low-income countries and to more than half of cases in high-income countries would close the current gap by 29–39%; the use of separate target coverage rates for low-income, middle-income, and high-income countries reflects differences in which they stand now with respect to treatment coverage, and are intended to reflect what has been achieved through programme scale-up efforts in countries such as Chile and the UK. Because of even lower starting coverage levels, the modelled gap reduction for anxiety disorders is lower than for depression (16–25%).

Effect of labour force on treatment
We modelled the economic effect of decreased morbidity in terms of increased participation in and increased productivity of the workforce. With regards to labour force participation, very few studies have assessed the extent to which effective depression treatments get people back into work, and when measured, estimates have been subject to local factors such as prevailing levels of unemployment in the economy (panel 2). For our base case, we conservatively modelled a 5% restored ability to work as a result of treatment, with half and double that rate used under pessimistic and optimistic scenario analyses. Impaired productivity was assessed both with respect to whole days off work (absenteeism) and also partial days of impaired activity while an individual is at work (presenteeism). Compared with adults without common mental disorders in a range of low-income, middle-income, and high-income countries participating in the World Mental Health Survey, 4–15 more days out of role per year were recorded because of depression and 8–24 days because of generalised anxiety disorders; additional time lost per year due to presenteeism was 11–25 partial disability days for depression and 12–26 for generalised anxiety disorders. Again, there are few empirical studies upon which to base estimates of the effect of effective treatment of depression and anxiety on productivity, and these point towards small differences between intervention and control groups (panel 2). Expressed as a proportion of total working days per year (220 days), and allowing for both the onset of effect as well as the time lag between improved health and return to work, we modelled a 5% increase in working days as a result of reduced absenteeism, and a 5% increase through reduced presenteeism. Again, these baseline values were varied up and down by a factor of 2 and 0.5, respectively, in an uncertainty analysis. These losses in and returns to productivity were linked to the prevailing rates of labour participation in the working age population (age 15–65 years) and gross domestic product (GDP) per worker in each of the 36 assessed countries to calculate productivity losses at current levels of treatment coverage and productivity gains after scaled-up treatment. The model does not account for potential changes in retirement age or working patterns over time, although an increase in retirement age and more flexible working patterns might enhance the overall productivity gains by people with depression and anxiety with treatment.

Economic value of health benefits
Improvements in labour force outcomes represent the instrumental value of improved mental health after effective treatment of common mental disorders. Independent of this instrumental value, being alive and healthy is also valuable in itself. For this analysis, we followed the approach adopted by Stenberg and colleagues, who divided the overall value of a life-year into its economic (instrumental) and health (intrinsic) elements. For the Lancet Commission on Investing in health, the value of a 1 year increase in life expectancy in low-income and middle-income countries was estimated to be 2–3 times per person national income, and 1–6 times per person national income worldwide (using a discount rate of 3%). Stenberg and colleagues attributed two-thirds of that derived value to the instrumental components, which are measured here directly via the

<table>
<thead>
<tr>
<th></th>
<th>Current coverage</th>
<th>Target coverage</th>
<th>Current gap</th>
<th>Reduced gap</th>
<th>% gap reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depression</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-income countries</td>
<td>7%</td>
<td>34%</td>
<td>93%</td>
<td>66%</td>
<td>29%</td>
</tr>
<tr>
<td>Lower middle-income countries</td>
<td>14%</td>
<td>42%</td>
<td>86%</td>
<td>58%</td>
<td>32%</td>
</tr>
<tr>
<td>Upper middle-income countries</td>
<td>21%</td>
<td>49%</td>
<td>79%</td>
<td>51%</td>
<td>35%</td>
</tr>
<tr>
<td>High-income countries</td>
<td>28%</td>
<td>56%</td>
<td>72%</td>
<td>44%</td>
<td>39%</td>
</tr>
<tr>
<td><strong>Anxiety disorders</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-income countries</td>
<td>5%</td>
<td>20%</td>
<td>95%</td>
<td>80%</td>
<td>16%</td>
</tr>
<tr>
<td>Lower middle-income countries</td>
<td>10%</td>
<td>30%</td>
<td>90%</td>
<td>70%</td>
<td>22%</td>
</tr>
<tr>
<td>Upper middle-income countries</td>
<td>15%</td>
<td>35%</td>
<td>85%</td>
<td>65%</td>
<td>24%</td>
</tr>
<tr>
<td>High-income countries</td>
<td>20%</td>
<td>40%</td>
<td>80%</td>
<td>60%</td>
<td>25%</td>
</tr>
</tbody>
</table>

* Treatment coverage was modelled to increase from current to target rates linearly.

Table 1: Current and target levels of scaled-up treatment coverage for depression and anxiety disorders (all interventions combined), by country income level
Panel 2: Labour force effects of treatment

Labour force participation
There are very few studies showing the extent to which effective depression treatments get people back into work. Two studies undertaken in the USA reported a 6% increase in employment retention in patients with depression whose care was monitored and managed closely.20,21 Findings of another US study22 of patients in primary care showed that, at 6 months, employment rates were 52-5% for patients with no care versus 72.2% for patients with care. For low-income and middle-income countries, programme evaluation data for livelihoods from four countries—China, India, Ghana, and Pakistan—were made available by BasicNeeds, which showed that the proportion of people with depression undertaking income-generating activities increased by more than 50%, and in those with anxiety by more than 30% (Chris Underhill, BasicNeeds, personal communication). These estimates are in line with the assessment of the BasicNeeds programme in Kenya, which for a more mixed caseload showed an 43% improvement in the proportion of enrollees in income generation or productive work.23 Because these data are based on observation rather than under controlled trial conditions, we can infer only a clear association between exposure to treatment and subsequent earnings rather than a definitive effect of intervention. For our base case, we therefore conservatively modelled a 5% restored ability to work as a result of treatment, with half and double that rate used under pessimistic and optimistic scenario analyses.

Labour force productivity
A comprehensive review of 440 published trials in an existing database of psychological and pharmaceutical interventions in depression44 was specifically undertaken for this project (by researchers at the Vrije Universiteit Amsterdam, Amsterdam, Netherlands, and the Trimbos Institute, Utrecht, Netherlands) to identify the effect of effective treatment on productivity; unfortunately, very few trials reported these effects. However, some treatment trials done in the USA, Korea, and India have estimated the effect of intervention on productivity loss. The decrease in absenteeism reported in these studies was close to 1 day per month.29-31 Only two studies reported the findings for presenteeism separately from days lost because of absenteeism: in the Korean study, treated patients had 24 more productive hours per month,31 whereas in the Indian study, patients receiving the collaborative care had 4 fewer partial days lost than controls.32 By conservatively assuming that 1 partial day is equivalent to a third of a whole day, we estimate that almost 1 complete day of unimpaired work is restored per month through reduced presenteeism. Expressed as a proportion of total working days per year (220 days), and allowing for both the onset of effect and the time lag between improved health and return to work, a 5% increase in working days is gained through reduced absenteeism, and a 5% increase through reduced presenteeism.

Uncertainty analysis
We assessed the sensitivity of results to plausible variations around these and other key input parameters by constructing optimistic and pessimistic scale-up scenarios. For the upper estimate: total investment costs were assumed to be 20% lower than baseline, as a result of lower than expected use of expensive hospital outpatient and inpatient care or the development of more efficient interventions, including internet-based treatments; and productivity effects were set at double their baseline rate (10% rather than 5%); the intrinsic value of a year of health life was set at 0·3 times GDP per person (rather than 0·5). For the lower estimate: total investment costs were assumed to be 20% higher than baseline, as a result of higher than expected drug prices, service use and programme management; productivity effects were set at half their baseline rate (2·5% rather than 5%); and the intrinsic value of a year of health life was set at 0·3 times GDP per person (rather than 0·5).

Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results
Across the 36 largest countries in the world, in the absence of scaled-up treatment, it is projected that more than 12 billion days of lost productivity (equivalent to more than 50 million years of work) are attributable to depression and anxiety disorders every year, at an estimated cost of US$925 billion. Assuming the same distribution of costs across lower-income and higher-income countries holds for all other countries (representing 20% of the world’s population), the global cost per year is $1·15 trillion. Compared with people without these disorders, 4·7 billion extra days are lost, at a cost of $592 billion (36% of the total cost); this figure can be termed the excess productivity loss of these disorders (figure I).

Table 2 shows the estimated cost of scaling up treatment for depression and anxiety, expressed as the net present value of the total expenditure required over the scaling-up period between 2016 and 2030 (ie, the cumulative cost over 15 years of steady scale-up, but discounted at a rate of 3%). These costs relate to incremental treatment coverage in the population over and above current levels of coverage. For all 36 countries, the total cost amounts to US$91 billion for depression and $56 billion for anxiety disorders. Treatment of mild cases accounts for less than 10% of total costs for depression and 20% for anxiety disorders.
disorders. After standardising for population size, the cost is actually quite low; for depression treatment, the average annual cost during 15 years of scaled-up investment is $0·08 per person in low-income countries, $0·34 in lower middle-income countries, $1·12 in upper middle-income countries and $3·89 in high-income countries (table 2). Per person costs for anxiety disorders are nearly half that of depression.

Table 2 shows results for two key health outcomes: cases averted (reduced prevalence) and healthy life-years gained (equivalent to disability-adjusted life-years averted). Across the 36 countries represented in the analysis, we recorded a small decrease in the estimated prevalence of depression and anxiety disorders as a result of treated cases recovering from illness more quickly; in the next 15 years, this gradual decrease in prevalence translates into millions of averted cases (73 million fewer cases of depression, and 45 million fewer cases of anxiety disorder). Weighting these averted prevalent cases by the average level of improved functioning or reduced disability provides a measure of healthy life-years gained. For depression and anxiety disorders combined, the cumulative number of healthy life-years gained over 15 years is 43 million.

Table 2 also shows the difference in aggregate GDP between a continued current coverage scenario and one reflecting scaled-up treatment and enhanced productivity; again, this and the total economic return for the entire period of scale-up has been discounted at 3% to give a net present value. For all 36 countries combined, the net present value is $399 billion ($230 billion for depression and $169 billion for anxiety disorders). The intrinsic value of health returns show a net present value of more than $250 billion for scaled-up depression treatment and more than $50 billion for anxiety disorders (table 2).

### Table 2: Costs and benefits of scaled up treatment of depression and anxiety disorders, 2016–30

<table>
<thead>
<tr>
<th></th>
<th>Low-income countries (N=6)</th>
<th>Lower middle-income countries (N=10)</th>
<th>Upper middle-income countries (N=10)</th>
<th>High-income countries (N=10)</th>
<th>All countries (N=36)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population of countries analysed (millions, 2013)</td>
<td>443</td>
<td>2215</td>
<td>2101</td>
<td>992</td>
<td>5751</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total investment (net present value, US$ millions)</td>
<td>517</td>
<td>7164</td>
<td>20338</td>
<td>63503</td>
<td>91522</td>
</tr>
<tr>
<td>Average annual investment (net present value, US$ per person)</td>
<td>0·08</td>
<td>0·34</td>
<td>1·12</td>
<td>3·89</td>
<td>1·50</td>
</tr>
<tr>
<td>Health returns (averted prevalent cases)</td>
<td>6 150 311</td>
<td>25 989 404</td>
<td>25 607 740</td>
<td>15 750 268</td>
<td>73 497 723</td>
</tr>
<tr>
<td>Health returns (healthy life-years gained)</td>
<td>2 234 781</td>
<td>15 692 290</td>
<td>11 414 429</td>
<td>7 567 211</td>
<td>36 908 731</td>
</tr>
<tr>
<td>Economic returns (US$ millions)</td>
<td>11 90</td>
<td>18 799</td>
<td>57 732</td>
<td>157 022</td>
<td>229 744</td>
</tr>
<tr>
<td>Value of health returns (US$ millions)</td>
<td>991</td>
<td>21 679</td>
<td>56 435</td>
<td>178 588</td>
<td>257 694</td>
</tr>
<tr>
<td>Benefit to cost ratio (economic returns)</td>
<td>2·3</td>
<td>2·6</td>
<td>2·6</td>
<td>2·5</td>
<td>2·5</td>
</tr>
<tr>
<td>Benefit cost ratio (economic and value of health returns)</td>
<td>4·2</td>
<td>5·7</td>
<td>5·4</td>
<td>5·3</td>
<td>5·3</td>
</tr>
<tr>
<td>Anxiety disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total investment (net present value, US$ millions)</td>
<td>304</td>
<td>3797</td>
<td>8966</td>
<td>42 668</td>
<td>55 735</td>
</tr>
<tr>
<td>Average annual investment (net present value, US$ per person)</td>
<td>0·05</td>
<td>0·16</td>
<td>0·52</td>
<td>2·44</td>
<td>0·88</td>
</tr>
<tr>
<td>Health returns (averted prevalent case)</td>
<td>3 395 363</td>
<td>16 597 190</td>
<td>12 980 180</td>
<td>12 077 953</td>
<td>45 052 336</td>
</tr>
<tr>
<td>Health returns (healthy life-years gained)</td>
<td>416 222</td>
<td>2 220 716</td>
<td>1 711 767</td>
<td>1 604 069</td>
<td>5 952 783</td>
</tr>
<tr>
<td>Economic returns (US$ millions)</td>
<td>824</td>
<td>11 578</td>
<td>26 601</td>
<td>129 795</td>
<td>168 797</td>
</tr>
<tr>
<td>Value of health returns (US$ millions)</td>
<td>181</td>
<td>2966</td>
<td>8453</td>
<td>40 409</td>
<td>52 009</td>
</tr>
<tr>
<td>Benefit cost ratio (economic returns)</td>
<td>2·7</td>
<td>3·0</td>
<td>3·0</td>
<td>3·0</td>
<td>3·0</td>
</tr>
<tr>
<td>Benefit cost ratio (economic and value of health returns)</td>
<td>3·3</td>
<td>3·8</td>
<td>3·9</td>
<td>4·0</td>
<td>4·0</td>
</tr>
</tbody>
</table>

*Healthy life-years gained multiplied by GDP per person multiplied by 0·5.
By summing the discounted costs and benefits for all countries in an income group, we derived a summary measure of the relationship between the benefits of scaled-up treatment and the associated costs of investment (table 2, figure 2). Restricting assessment to the economic returns to investment, benefit to cost ratios for scaled-up depression treatment across country income groupings were in the range of 2.3 to 2.6. For anxiety disorders the ratios were slightly higher (range 2.7–3.0). Extension of the benefit–cost analysis to include the estimated value of health returns increased the ratio of benefit to cost, especially for depression because of the higher health returns for this disorder compared with anxiety disorders. Benefit to cost ratios for depression now exceed those for anxiety disorders (range 4.2–5.7), and were more than double the ratio when only economic benefits of depression treatment scale-up were considered. Benefit to cost ratios for anxiety disorders increased by a third (range 3.3–4.0).

We did uncertainty analysis to ascertain the sensitivity of results to plausible changes in key study parameters. Benefit to cost ratios fell to or almost reached parity under the more pessimistic scenario when only economic benefits were considered, and did not exceed 3 even when the value of health benefits was included (figure 2). By contrast, the more optimistic scenario produces benefit to cost ratios of 5.5–7.2 (economic benefits only) and 7.5–11.3 when the value of health benefits was added in. As expected, results were quite sensitive to the estimated rate of enhanced labour participation and productivity. We also assessed the effect of changing the rate used to discount future costs and benefits to the present time. At a discount rate of 6%, the net present value of total investments and returns would be 25% less; with no discounting, they would be 35% higher in absolute terms. Because such a change in discount rate was applied to both costs and benefits, the ratio of benefit to cost, our summary return on investment metric, is not affected.

Discussion
This analysis sets out, for the first time, a global investment case for a scaled-up response to the massive public health and economic burden of depression and anxiety disorders. Previous international economic studies of mental health have assessed the economic effect of these disorders,1,2 the cost-effectiveness of different intervention strategies,3,4 and the cost of scaling up care,5,6 but not the value of both economic and health benefits of intervention scale up.

Notwithstanding the general limitations of any projection modelling study, the analysis suggests that the investment needed to substantially scale up effective treatment coverage for depression and anxiety disorders in the 36 countries included in this analysis is substantial; the net present value of all investments between 2016 and 2030 is $147 billion, equivalent to less than $10 billion per year on average. Extending the scope to the 20% of the world’s population not living in the 36 countries represented in the study would increase the cost by about 25% to $184 billion. However, the returns to this
investment are also substantial, with benefit to cost ratios of 2.3–3.0 when economic benefits only are considered, and 3.3–5.7 when the value of health returns are also included. To put these findings into context, any benefit to cost ratio exceeding 1 provides a rationale for investment. Compared with some other potential investments in health, ratios of the order reported here can be deemed relatively modest. For example, a return on investment analysis for malaria, also for 2016–30, but using the full value of a statistical life-year, estimated benefit to cost ratios in the range of 28.1 to 40.1. An investment case done for maternal, reproductive, neonatal, and child health obtained a benefit to cost ratio of less than 10:1 for 2013–35, which is closer to the results obtained in this study. Inclusion of other benefits arising from scaled-up treatment of common mental disorders that could not be captured though the present modelling exercise, notably reduced welfare support payments, and improved outcomes for other affected people (eg, partners and children of women with perinatal depression) would generate higher ratios of benefit to cost. Set against that, treatment programmes might cost more or achieve less than anticipated, as highlighted by the uncertainty analysis.

One limitation of our study is that although the projected level of overall prevalence of depression and anxiety disorders is quite well-established, the same cannot be said for treated prevalence. The analysis done here allows for a gradual linear increase in effective service coverage for depression and anxiety disorders in all parts of the world in the next 15 years. However, for this to happen, not only will a new level of political commitment and resource mobilisation be required, but also a significant reorientation of public health systems towards chronic disease identification and management. Partial or weak implementation of envisaged treatment programmes, including appropriate management of recurrent cases of depression or insufficient promotion and awareness programmes, will inevitably reduce the number of cases effectively reached and therefore the health and other benefits obtained. It is also possible that as treatment coverage in the population increases substantially, the average cost per case might go up, for example as a result of reaching out to more remote or less well-served parts of a country. Target coverage rates were accordingly set at a modest level in this analysis (an upper value of 56% of depression cases in high-income countries). Aside from projected treatment coverage and effectiveness, a further crucial parameter for this analysis concerns the effect of treatment on labour force participation and productivity, for which there remains a paucity of evidence. As concluded by a systematic review, such data are not hard to collect alongside clinical trials and other studies, and need to be uniformly measured more often. More generally, population health models (eg, the OneHealth tool) rely on many input parameters, data sources, and assumptions regarding expected rates of disease, demographic change, and intervention effects in the future, which limits their precision.

Several effects were not included in the analysis. One was the negative effect of maternal depression on early child development, for which there is clear evidence. The health, social, and economic benefits of effective treatment of maternal depression on the cognitive and physical development of newly born babies was not assessed, but there is some evidence that this could be substantial over the longer term. Likewise, the monetary and non-monetary impact of effective treatment on family and other caregivers has not been factored in. Additionally, no account has been taken of the substantial effect of depression and its treatment on physical health outcomes; depression is a risk factor for disorders such as hypertension, stroke, coronary heart disease, and substance use disorders (just as these conditions are risk factors for depression), and adversely affects outcomes through reduced help-seeking and adherence. Inclusion of these additional effects of treatment would bolster identified economic returns. Taking appropriate account of the regular co-occurrence of depression and anxiety in individuals would be expected to lead to strong synergies on the treatment side, leading to potentially reduced investment costs, but health and economic outcomes for these comorbid cases might be slower or harder to achieve.

Although the analysis accounted for age and sex (eg, in terms of disease prevalence, labour force participation and treatment eligibility), it was not possible to consider the effect of socioeconomic status as a mediator and predictor of good health and economic outcomes. Poverty has an adverse effect on the risk of depression and anxiety disorders through higher levels of stress, social exclusion, violence and trauma, but the evidence base for the mental health effect of interventions targeted at the poor remains insubstantial. In many countries, poor people face significant barriers to accessing services, including the financial cost of seeking and paying towards health care. Finally, it should be acknowledged that the workplace itself can be a source of stress for many people, and that there is a consequent need to integrate mental health and wellbeing into new or existing employee support programmes.

A crucial issue related to but outside the scope of this return on investment analysis is the source of financing for investments required to scale-up services for depression and anxiety disorders. As previously noted, the absolute amount needed for investment (eg, on a per person basis) is modest, but because existing service coverage level is so low in most countries, the gap between current and required spending can be large. Accordingly, both rich and poor countries need to carefully consider the merits of different health financing mechanisms. For many countries, the first question to address concerns the extent to which domestic financing
represents a feasible and sufficient method for financing mental health services, perhaps as part of a package of measures to be paid for from enhanced revenue generation. For low-income countries eligible for official development assistance, a second question might be to what extent external funding can complement domestically generated resources to catalyse service development. In countries where domestic or external funding mechanisms are expected to fall short of requirements or pose a risk to fiscal stability, a further question relates to the extent to which market-based financing options such as bonds offer a suitable and feasible approach to generating and providing funds for outcomes-based scale-up for mental health services.

The pursuit of any of these methods of financing will be affected by other factors, including the amount of investment needed, the level of political will and also fiscal space for raising new resources for health, and eligibility of the country for bilateral or multilateral funding. Faced with a new and broad development eligibility of the country for bilateral or multilateral fiscal space for raising new resources for health, and investment needed, the level of political will and also be affected by other factors, including the amount of resources that leads to clear and definable health, represents a sound and equitable investment of society’s resources for common mental disorders and the health sector more situation, can contribute to a balanced investment case needs and priorities, and the broader macro-fiscal development. In countries where domestic or external funding mechanisms are expected to fall short of necessarily represent the decisions, policy, or views of WHO.

Contributors
DC and SS conceived, planned, and oversaw the study. DC led the analysis of treatment costs and health outcomes, and drafted the paper. KS led the development of the methodology and model for estimating productivity effects. PS and BR contributed to the conceptual development of the return on investment model and its constituent parts. PC and FS led the systematic review of productivity effects of treatment. All authors reviewed, commented on, and approved the report.

Declaration of interests
We declare no competing interests.

Acknowledgments
We thank the contribution of Chris Underhill, Jess McQuail, and Uma Sunder of BasicNeeds, who provided country-level data for productivity outcomes for people enrolled into their mental health and development programme; colleagues in the Department of Health System Governance and Financing (Jeremy A Lauer and Melanie Bertram) regarding conceptualisation and review of return on investment frameworks in health, and Eirini Karyotaki at VU Amsterdam University for her contribution to a systematic review; Shelly Chopra for her contribution to a background literature search and to the development of the conceptual framework used in this study.

Development of the mental health module of the OneHealth tool, which was used in this analysis for estimating health impacts, was made possible through the EMERALD project on mental health system strengthening in low-income and middle-income countries, which is funded by the European Union under the 7th Framework programme (Grant agreement 305068). DC and SS are staff members of WHO. All opinions expressed in this report rest with the authors; they do not necessarily represent the decisions, policy, or views of WHO.

References
10 Chisholm D, Saxena S. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ 2012; 344: e609.

*BMC Psychiatry* 2008; 8: 36.


*Value Health* 2011; 14: 475–82.

*Bull World Health Organ* 2012; 90: 813–21.

*Arch Gen Psychiatry* 2005; 62: 1332–41.


*Bull World Health Organ* 2013; 91: 593–601.

